The Translational Research Institute (TRI), based in Brisbane, Queensland, and the Queensland Government have collaborated on The Translational Manufacturing Facility (TM@TRI).
Construction of the Translational Manufacturing Facility (TM@TRI) is advancing rapidly, with scaffolding coming down, windows and exterior panels being installed, and preparations for the roof nearing completion.
Key team members from TRI were given an exclusive preview of the site, which revealed expansive interior spaces, including the atrium, cleanrooms, laboratories, and a collaborative area.
Set to open in early 2026, TM@TRI will be Australia's first on-demand cGMP cleanroom facility, supporting high-potential biotech, pharmaceutical, and medtech companies.
TM@TRI will be Australia's first on-demand cGMP cleanroom facility
In addition to supporting local biomed startups, the facility has attracted interest from the $280 million Translational Science Hub.
This international collaboration between Queensland researchers and Sanofi scientists in France and the US will focus on the evaluation of new mRNA vaccines and the development of a world-first chlamydia vaccine.
The Hub is expected to generate 200 highly-skilled jobs in science, research, and healthcare, contributing to the sector’s growth.
This facility will help retain Australian biotech startups
TM@TRI, a $100 million investment from TRI and the Queensland Government, will cover 7,000m² across four floors, making it the largest end-to-end translational research facility in Australia.
It will provide a range of services, including in-house Quality Assurance, controlled raw material storage, cGMP consultancy, and specialist equipment support.
By offering a comprehensive environment for research and commercialisation, TM@TRI will help retain Australian biotech startups, reducing the need for them to go offshore.
Top image: The Translational Research Institute (TRI) facility in progress